Prospera™
for Kidney Transplant Assessment

Covered by Medicare, Prospera™ is a transplant rejection assessment test that uses a simple blood draw to evaluate the risk of rejection of a transplanted kidney.

Through the use of advanced cell-free DNA technology, Prospera™ increases a provider’s ability to identify otherwise undetected rejection that might lead to kidney loss. Catching transplant rejection as soon as possible can help providers develop a treatment plan to best protect the donated kidney.

Setting a New Standard Through Research

Best-in-class care depends on best-in-class assessment

Prospera™ innovation is backed by deep data – reinforced by ongoing research efforts.

ProActive Registry Study: Completed Enrollment

Largest clinical utility study evaluating cell-free DNA; includes more than 3,000 kidney transplants studied for three years
Long-term assessment of high-risk recipients for up to 5 years post-transplantation
Personalized transplant management protocols using cell-free DNA data

Visit the ProActive Study
Read about ProActive Recruitment Milestone
View study

Trifecta Study with the Molecular Microscope Diagnostic System (MMDX) Published

Global, prospective multicenter study under the leadership of Dr. Philip Halloran
300 patients to be comprehensively evaluated with clinical information, cell-free DNA measures, biopsies, molecular microscope, evaluations, and donor-specific antibodies (DSA)
Integrated data analysis to better inform non-invasive and interventional management in kidney transplantation

Visit the clintrials.gov page
Read the publication: Halloran et al, Prospera with the Two Threshold Algorithm
Halloran DSA
Gauthier et al publication

PEDAL Study: Completed Enrollment

500 kidney transplant patients from 20 major US centers
Evaluation of how quantifying the absolute concentration of background cell-free DNA (cfDNA) may allow for a more precise and confident assessment of allograft rejection — especially in identifying patients at-risk of false-negative interpretations

500 patients from 28 centers
CONCERT Study: To accelerate clearance for renal transplantation in molecular residual disease (MRD)-negative patients with a history of colorectal cancer
PARC Study: To understand how malignancies and cancer therapy affect background cell-free DNA levels in renal allograft patients
SIGNAL Study: To observe Signatera in patients with liver cancer to determine molecular residual disease (MRD) rates before and after liver transplant

Sigdel et al Clinical Validation: Published in 2019

Conducted with the University of California, San Francisco
Largest biopsy-matched study conducted in renal transplantation assessing the use of cell-free DNA
The first to publish performance of cell-free DNA testing in subclinical, surveillance setting

View: Sigdel et al paper

MOTR Study: Completed Enrollment

Study to determine utility of Prospera in multiple organ transplant patients
Evaluate 400 kidney-liver, kidney-pancreas and kidney-heart patients

Talk to us

Is Prospera™ right for you?

We’re here to help you find out

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

Prospera™for Kidney Transplant Assessment